Givinostat Slows Duchenne Muscular Dystrophy Decline
Givinostat (Duvyzat) slowed physical decline as measured by stair climbing speed for a subset of boys with Duchenne muscular dystrophy (DMD), according to the phase III trial that supported the drug’s recent approval for this indication. While the boys still declined over 72 weeks on the oral drug, their times for a four-stair climb assessment […]
CPAP Turns in Mixed Results for Patients With Diabetic Eye Disease
Long-term use of continuous positive airway pressure (CPAP) slowed the progression of eye disease in sleep apnea patients with non-proliferative diabetic retinopathy, a small randomized study showed, but patients who adhered to the intervention ended up with more retinal microhemorrhages. In the single-center trial, the group assigned to a year of CPAP atop usual care […]
Donanemab Slows Progression in Early Alzheimer’s
AMSTERDAM — Investigational donanemab significantly slowed clinical progression at 76 weeks in people with early symptomatic Alzheimer’s disease who had amyloid and tau pathology, the phase III TRAILBLAZER-ALZ 2 trial showed. The drug, which targets a modified form of beta amyloid known as N3pG, showed significant slowing versus placebo on measures of cognition and daily […]
Practice-Changing Study in Advanced Cervical Cancer
Adding pembrolizumab (Keytruda) to chemotherapy with or without bevacizumab (Avastin) significantly slowed progression of metastatic cervical cancer and improved overall survival (OS), investigators in a randomized trial concluded. Median progression-free survival (PFS) improved from 8.2 months with chemotherapy plus or minus bevacizumab (Avastin) to 10.4 months with the addition of the PD-1 inhibitor. Comparison of […]